Download PDF
Thromb Haemost 1995; 74(04): 1015-1019
DOI: 10.1055/s-0038-1649871
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia

Giovanni Davì
1   The Department of Internal Medicine, University of Chieti, Italy
,
Antonina Ganci
The Department of Internal Medicine, University of Palermo, Italy
,
Maurizio Averna
The Department of Internal Medicine, University of Palermo, Italy
,
Carlo Giammarresi
The Department of Internal Medicine, University of Palermo, Italy
,
Carlo Barbagallo
The Department of Internal Medicine, University of Palermo, Italy
,
Isabella Catalano
The Department of Internal Medicine, University of Palermo, Italy
,
Anna Calà
The Department of Internal Medicine, University of Palermo, Italy
,
Alberto Notarbartolo
The Department of Internal Medicine, University of Palermo, Italy
› Author Affiliations
Further Information

Publication History

Received 07 November 1994

Accepted after resubmission 06 July 1995

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Thromboxane (Tx) A2 biosynthesis is enhanced in the majority of patients with type IIa hypercholesterolemia. Because blood clotting activation is an important component of the inflammatory response, involved in the initiation and progression of atherosclerotic plaques, we have investigated TxA2 biosynthesis, neutrophil activation and thrombin generation in 24 patients with type IIa hypercholesterolemia.

Urinary 11-dehydro-TxB2, was significantly higher (p =0.0001) in patients than in 24 sex- and age matched healthy subjects. Similarly, prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complexes and plasma elastase were significantly higher in patients than incontrols. Urinary 11-dehydro-TxB2 excretion was correlated with plasma elastase (r = 0.758; p =0.000I), and prothrombin fragment 1+2 (r = 0.804; p = 0.001). The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (20 mg/day for 2 months) significantly reduced cholesterol levels, urinary 11-dehydro-TxB2 excretion, plasma elastase and plasma Fl+2 in 8 patients.

We conclude that type IIa hypercholesterolemia is associated with biochemical evidence of platelet, neutrophil and blood clotting activation. The relationship between these events remains to be investigated.

 

  • References

  • 1 Ross R. The pathogenesis of atherosclerosis. In: Heart Disease. Braunwald E. ed. Philadelphia: Saunders; 1988: 1135-1152
    Search in Google Scholar
  • 2 Schrör K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. Eicosanoids 1990; 3: 67-73
    PubMedSearch in Google Scholar
  • 3 Davi G, Avema M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type Ha hypercholesterolemia. Circulation 1992; 85: 1792-1798
    CrossrefPubMedSearch in Google Scholar
  • 4 Prisco D, Rogasi PG, Paniccia R, Coppo M, Abbate R, Gensini GF, Neri Semeri GG. Altered lipid composition and thromboxane A2formation in platelets from patients affected by type Ha hyperlipoproteinemia. Thromb Res 1988; 50: 593-604
    CrossrefPubMedSearch in Google Scholar
  • 5 Henson PM. Interactions between neutrophils and platelets. Lab Invest 1990; 62: 391-393
    PubMedSearch in Google Scholar
  • 6 Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon III RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90: 35-41
    CrossrefPubMedSearch in Google Scholar
  • 7 Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature 1993; 362: 801-809
    CrossrefPubMedSearch in Google Scholar
  • 8 Ricevuti G, Mazzone A, Pasotti D, de Servi S, Specchia G. Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991; 9: 1-14
    PubMedSearch in Google Scholar
  • 9 Harlan IM. Consequence of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin Thromb Haemost 1987; 13: 434-444
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Rapaport SI, Rao VM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscl Thromb 1992; 12: 1111-1121
    CrossrefPubMedSearch in Google Scholar
  • 11 WHO Memorandum. Classification of hyperlipidemias and hyperlipoproteinemias. Circulation 1972; 45: 501-508
    CrossrefPubMedSearch in Google Scholar
  • 12 Roschlau P. Enzymatische Bestimmung des Gesamtecholesterins in Serum. Chem Klin Biochem 1974; 12: 226-227
    PubMedSearch in Google Scholar
  • 13 Wahalefeld AW. Triglyceride determination after enzymatic hydrolysis. In: ”Methods of enzymatic analysis”. Bergmeyer HU. ed. New York: Academic Press; 1974. 4 1831-1835
    Search in Google Scholar
  • 14 Lopez-Virella HF, Stone P, Ellis J, Colwell LA. Cholesterol determination in the HDL separated by precipitation with polianions. J Lipid Res 1970; 11: 583-595
    PubMedSearch in Google Scholar
  • 15 Becker W, Schafer W, Ziebenbein W. Standardization of immunochemical quantification of human apolipoprotein A and B. La Ricerca Clin Lab 1980; 10: 203-212
    CrossrefPubMedSearch in Google Scholar
  • 16 Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a). J Lipid Res 1977; 18: 331-338
    PubMedSearch in Google Scholar
  • 17 Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1980; 18: 499-502
    PubMedSearch in Google Scholar
  • 18 Avema MR, Barbagallo CM, Galione A, Carroccio A, Labisi M, Marino G, Montalto G, Notarbartolo A. Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: a comparison with type IV hyperlipoproteinemic patients. Metabolism 1989; 38: 1-2
    PubMedSearch in Google Scholar
  • 19 Ciabattoni G, Maclouf J, Catella F, FitzGerald A, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B2in human plasma and urine. Biochim Biophys Acta 1987; 918: 292-297
    PubMedSearch in Google Scholar
  • 20 Ciabattoni G, Puglicse F, Davi G, Pierucci A, Simonctti BM, Patrono C. Fractional conversion of thromboxane B2to urinary H-dehydrothromboxane B2in man. Bioehim Biophys Acta 1089; 992: 66-70
    PubMedSearch in Google Scholar
  • 21 Pelzcr H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment I + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Mock YA, Shirk A, ten Cate JW, Lamping RJ, Berends F, Bonn JJ J. Laboratory and clinical evaluation of an assay of (hrombin-antithrombin III (TAT) complexes in plasma. Clin (Tern 1988; 34: 2058-2062
    PubMedSearch in Google Scholar
  • 23 Neumann S, Gunzer G, Henrieh N, Lang H. PMN elastase assay. Enzyme immunoassay lor human polymorphonuclear elastase complexed with alpha-1-proteinase inhibitor J Clin Chem Clin Biochem 1984; 22: 693-697
    PubMedSearch in Google Scholar
  • 24 De Servi S, Mazzone A, Rieevuti G, Fioravanti A, Bramucci E, Angoli L, Ghio S, Specchia D. Granulocyte activation alter coronary angioplasty in humans. Circulation 1990; 82: 140-146
    CrossrefPubMedSearch in Google Scholar
  • 25 Siegel S. Nonparametric Statistics for the Behavioral Sciences. McGrawHill Book Co; New York: 1986. pp 184
    Search in Google Scholar
  • 26 Tremoli L, Colli S, Maderna P, Baldassarre D, Di Minno G. Hypercholesterolemia and platelets. Semin Thromb Haemost 1993; 19: 115-21
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Strano A, Davi G, Averna M, Rini GB, Novo S, Di Lede G, Mattina A, Notarbartolo A. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thromb Haemost 1982; 48: 18-21
    PubMedSearch in Google Scholar
  • 28 Tremoli E, Folco G, Agradi E, Cialli C. Platelet thromboxane and serum cholesterol. Lancet 1979; 1: 107-108
    PubMedSearch in Google Scholar
  • 29 Stragliotto H, Camera M, Postiglione A, Sirtori M, Di Minno G, Tremoli E. Functionally abnormal monocytes in hypercholesterolemia. Arterioscl Thromb 1993; 13: 944-950
    CrossrefPubMedSearch in Google Scholar
  • 30 Weissmann G, Smolen JE, Korehak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Meil 1980; 303: 27-34
    PubMedSearch in Google Scholar
  • 31 Weksler BB, JalTe LA, Brower MS, Cole OF. Human leukocyte cathepsin (i and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells. Blood 1989; 74: 1627-1634
    PubMedSearch in Google Scholar
  • 32 Reneslo P, Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood 1993; 82: 139-144
    PubMedSearch in Google Scholar
  • 33 Bauer KA, Rosenberg RD. The pathophysiology of prothrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
    PubMedSearch in Google Scholar
  • 34 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Catlaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
    CrossrefPubMedSearch in Google Scholar
  • 35 Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscl Thromb 1995; 15: 247-251
    CrossrefPubMedSearch in Google Scholar